The Idiot Index

Applied to pharmaceutical and integrated healthcare companies. COGS captures manufacturing of drugs, devices, and clinical services; R&D in this sector is capitalized into pipeline value rather than expensed-and-forgotten, so the Shareholder Extraction ratio carries explicit weight as an indicator of capital allocation priority.

Required disclosure under Dodd-Frank Section 953(b) since 2018. Filed in DEF 14A proxy statements. The dashboard aggregates the disclosure across the top 50 and ranks.

Source data: CEO total compensation and median employee compensation, both as filed in the company's most recent DEF 14A. When the ratio is XBRL-tagged we use the tagged value; otherwise the narrative disclosure is parsed (~99% accuracy).